Fagron Compounding Services, LLC

Fagron Compounding Services, LLC, doing business as Fagron Sterile Services, manufactures and delivers sterile compounded pharmaceuticals and pharmacy supplies to federal healthcare agencies as a prime contractor under total small business set-asides, with headquarters in Wichita, Kansas, and a foreign-owned corporate structure classified under NAICS 325412 (Pharmaceutical Preparation Manufacturing).

The vendor's federal footprint is heavily concentrated in defense and federal healthcare customers. The top two customers by potential value are the Department of the Army Medical Command (2 awards, $1.7 million combined potential value) and the Defense Health Agency (10 awards, $628 thousand combined potential value), together representing $2.3 million of the vendor's $2.8 million in total combined potential value across all awards. The Department of Health and Human Services Indian Health Service contributes 3 awards totaling $419 thousand, while the Department of Veterans Affairs Veterans Integrated Service Networks contribute 3 awards totaling $80 thousand. These five customer agencies account for 100% of recent award activity.

The core vehicle anchoring Fagron's work is a single-award Indefinite Delivery, Indefinite Quantity contract (W81K0024D0003) with the U.S. Army Medical Command valued at $1.78 million through September 30, 2029, designated as a total small business set-aside. This IDIQ contract, awarded October 1, 2024, supports Brooke Army Medical Center in San Antonio, Texas, with 11 delivery orders to date carrying $628 thousand in combined potential value. The Defense Health Agency has issued all eleven delivery orders under this vehicle, ordering compounded pharmaceuticals including phenylephrine, fentanyl, rocuronium, succinylcholine, and hydromorphone on a firm fixed-price basis. Representative delivery orders include a $356.9 thousand order (October 1, 2026, completion September 30, 2030), a $61.9 thousand order (April 29, 2025, completion June 30, 2025), and a $47.3 thousand order (October 1, 2025, completion September 30, 2026). Outside the IDIQ, Fagron holds a total small business set-aside blanket purchase agreement with the Indian Health Service for sterile compounded pharmaceuticals to Gallup Indian Medical Center, valued at $163 thousand (award April 7, 2026, completion April 6, 2028), and prior purchase orders with the Department of Veterans Affairs for ophthalmic solutions and pharmacy supplies.

Activity has accelerated significantly — one award in 2023, five in 2024, and eight in 2025 — with only two awards (combined potential value $254 thousand) reaching ultimate completion within the next twenty-four months. All eighteen awards are prime contracts; the vendor does not subcontract within the federal portfolio. Fagron's capability set focuses entirely on specialized sterile compounded medications, ophthalmic preparations, and pharmacy supply delivery to military and federal healthcare systems, with no diversification into other service categories or customer agencies visible in the recent award history.